| Project/Area Number |
21591617
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Kitasato University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
JIANG Shi-xu 北里大学, 医学部, 講師 (70276153)
MITSUFUJI Hisashi 北里大学, 医学部, 講師 (40260856)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2011: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Keywords | 肺癌 / 放射線療法 / 定位放射線治療 / 分子標的薬 / EGFR / 化学放射線療法 / シスプラチン / ビノレルビン / Gefitinib / EGFR遺伝子 / EGFR-TKI / 放射線治療 |
|---|
| Research Abstract |
In the patients with peripheral stage I non-small cell lung cancer treated with stereotactic body radiotherapy, the 5-year overall survival rate, cause-specific survival rate and local progression-free rate were 63%, 74% and 72%, respectively. But the patients with squamous cell carcinoma of the lung had a worse prognosis. The immunohistochemical study for EGFR mutation showed that the heterogeneity of gene mutation commonly developed in the various types of lung cancer. The 6B6 antibody staining was specific for EGFR mutation and considered to be useful for screening patients effective to EGFR TKI.
|
